COOKIE NOTICE
This site uses cookies to store information on your computer. We use cookies to get a better
understanding of how you navigate our site and to give you the best personalized experience. To
learn more about cookies and their benefits, please read our Privacy
Policy. By accepting this message, you consent to our use of cookies on this device, unless
you have disabled them.
Accept
AveXis is a Novartis Company
Global |
U.S.
MENUCLOSE
About Us
老王微皮恩最新破解版
Manufacturing
Research + Development
Patients + Families
Understanding SMA
Managed Access Program
Patient
Resources
Healthcare Professionals
Research Grants
老王微皮恩最新破解版
Careers
Media
Transparency + Disclosure
About Us
Our People + Values
Manufacturing
Research + Development
Patients + Families
Understanding SMA
Managed Access Program
Patient Resources
Healthcare Professionals
Research Grants
Medical Education Grants
Careers
Media
Transparency + Disclosure
ChainL2025-outline
AveXis is dedicated to developing and commercializing gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases.
ChainL2025-outline
Jun 01, 2025
AveXis Community Statement on Global Managed Access Program for AVXS-101
By clicking this link, you will be leaving AveXis.com to go to a site
that is not controlled or endorsed by AveXis. AveXis provides links to third-party sites as
a convenience. AveXis is not responsible for the content of these sites or any of its
further links. Each of these sites has their own privacy policy and terms of use. Thank you
for visiting AveXis.com.